Document is current
Any future updates will be listed below
-
Authors
Harjuhaahto, Sandra
Jokela, Manu
Rajendran, Jayasimman
Rokka, Minea
Hu, Bowen
Kvist, Jouni
Zhang, Fuping
Zárybnický, Tomáš
Haimilahti, Kimmo
Euro, Liliya
Pirinen, Eija
Huber, Nadine
Herukka, Sanna-Kaisa
Haapasalo, Annakaisa
Kuuluvainen, Emilia
Gopalakrishnan, Swetha
Katajisto, Pekka
Hietakangas, Ville
Burg, Thibaut
Van Den Bosch, Ludo
Huang, Xiaoping
Narendra, Derek P.
Kuure, Satu
Ylikallio, Emil
Tyynismaa, Henna
-
Funding
Funding for this research was provided by:
University of Helsinki
- License Information
-
More Information
Article History
Received: 21 February 2025
Accepted: 12 May 2025
First Online: 22 May 2025
Declarations
:
: Animal experiments were performed in compliance with the national ethical guidelines set by the European Union and were approved by the National Animal Experiment Board (Project Authorisation Board, project license ESAVI-12691-2021). The ethical practice of handling laboratory animals was strictly followed throughout the procedures. The generation of the human induced pluripotent stem cell lines used in this study was approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District (Nro 423/13/03/00/08) with informed consent of the donor.
: Written and informed consent of patient was received prior examination for results and the usage of photographs for publication.
: The authors declare that they have known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. L.E. is a co-founder of NADMED Ltd. L.V.D.B. is the scientific founder of Augustine Therapeutics and is head of the Scientific Advisory Board. L.V.D.B. is also part of the Investment Advisory Board of Droia Ventures (Meise, Belgium). Authors declare no other conflicts of interest.
